<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38084725</PMID><DateCompleted><Year>2024</Year><Month>04</Month><Day>03</Day></DateCompleted><DateRevised><Year>2024</Year><Month>12</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1502-7708</ISSN><JournalIssue CitedMedium="Internet"><Volume>59</Volume><Issue>4</Issue><PubDate><Year>2024</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Scandinavian journal of gastroenterology</Title><ISOAbbreviation>Scand J Gastroenterol</ISOAbbreviation></Journal><ArticleTitle>Increasing the transplant dose and repeating faecal microbiota transplantation results in the responses of male patients with IBS reaching those of females.</ArticleTitle><Pagination><StartPage>391</StartPage><EndPage>400</EndPage><MedlinePgn>391-400</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1080/00365521.2023.2292479</ELocationID><Abstract><AbstractText Label="BACKGROUND">Faecal microbiota transplantation (FMT) performed with a proper protocol is a safe treatment for IBS that has high efficacy and durable effects. Females have been reported to respond better than males to FMT. The present study aimed at determining whether increasing the transplant dose or repeating FMT improve the responses of males to FMT.</AbstractText><AbstractText Label="METHODS">This study included 186 IBS patients (131 females and 55 males) who were randomized at a 1:1:1 ratio to receive 90&#x2009;g of donor faeces once into the large intestine, once into the small intestine or twice into the small intestine. Patients completed five questionnaires that assessed their symptoms and quality of life, and provided faecal samples at baseline and at 3, 6 and 12&#x2009;months after FMT. The faecal bacterial profile and dysbiosis index were determined using 16S rRNA gene PCR DNA amplification covering variable genes V3-V9.</AbstractText><AbstractText Label="RESULTS">The response rates to FMT at all observation times did not differ significantly between females and males regardless of the transplant administration route or whether it was repeated. Faecal <i>Alistipes</i> levels were higher in females than in males at baseline and increased in both females and males after FMT. In the repeated group, the <i>Alistipes</i> levels did not differ between females and males after FMT.</AbstractText><AbstractText Label="CONCLUSIONS">Increasing the transplant dose and repeating FMT results in the responses of male IBS patients to FMT reaching those of females regardless of the administration route. <i>Alistipes</i> spp. levels appear to play a role in this improvement.www.clinicaltrials.gov (NCT04236843).</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>El-Salhy</LastName><ForeName>Magdy</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medicine, Stord Hospital, Stord, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Clinical Medicine and Department of Gastroenterology, University of Bergen, Bergen, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gilja</LastName><ForeName>Odd Helge</ForeName><Initials>OH</Initials><AffiliationInfo><Affiliation>Department of Clinical Medicine and Department of Gastroenterology, University of Bergen, Bergen, Norway.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>National Centre for Ultrasound in Gastroenterology, Haukeland University Hospital, Bergen, Norway.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hatlebakk</LastName><ForeName>Jan Gunnar</ForeName><Initials>JG</Initials><AffiliationInfo><Affiliation>Department of Clinical Medicine and Department of Gastroenterology, University of Bergen, Bergen, Norway.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT04236843</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>12</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Scand J Gastroenterol</MedlineTA><NlmUniqueID>0060105</NlmUniqueID><ISSNLinking>0036-5521</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012336">RNA, Ribosomal, 16S</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069467" MajorTopicYN="N">Fecal Microbiota Transplantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D043183" MajorTopicYN="Y">Irritable Bowel Syndrome</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012336" MajorTopicYN="N">RNA, Ribosomal, 16S</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000069196" MajorTopicYN="Y">Gastrointestinal Microbiome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005243" MajorTopicYN="N">Feces</DescriptorName><QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alistipes spp</Keyword><Keyword MajorTopicYN="N">faecal microbiota transplantation</Keyword><Keyword MajorTopicYN="N">fatigue</Keyword><Keyword MajorTopicYN="N">non-responders</Keyword><Keyword MajorTopicYN="N">responders</Keyword><Keyword MajorTopicYN="N">sex</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>4</Month><Day>3</Day><Hour>6</Hour><Minute>44</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>12</Month><Day>12</Day><Hour>12</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>12</Month><Day>12</Day><Hour>7</Hour><Minute>48</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38084725</ArticleId><ArticleId IdType="doi">10.1080/00365521.2023.2292479</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>